JP2019535670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535670A5 JP2019535670A5 JP2019521046A JP2019521046A JP2019535670A5 JP 2019535670 A5 JP2019535670 A5 JP 2019535670A5 JP 2019521046 A JP2019521046 A JP 2019521046A JP 2019521046 A JP2019521046 A JP 2019521046A JP 2019535670 A5 JP2019535670 A5 JP 2019535670A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410162P | 2016-10-19 | 2016-10-19 | |
| US62/410,162 | 2016-10-19 | ||
| US201762472209P | 2017-03-16 | 2017-03-16 | |
| US62/472,209 | 2017-03-16 | ||
| PCT/CA2017/051245 WO2018072025A1 (en) | 2016-10-19 | 2017-10-19 | Cd133-binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535670A JP2019535670A (ja) | 2019-12-12 |
| JP2019535670A5 true JP2019535670A5 (enExample) | 2020-11-26 |
| JP7231158B2 JP7231158B2 (ja) | 2023-03-01 |
Family
ID=62018307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521046A Active JP7231158B2 (ja) | 2016-10-19 | 2017-10-19 | Ｃｄ１３３結合剤およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11220551B2 (enExample) |
| EP (1) | EP3529279A4 (enExample) |
| JP (1) | JP7231158B2 (enExample) |
| CN (1) | CN110352198B (enExample) |
| WO (1) | WO2018072025A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3054104A1 (en) * | 2017-03-27 | 2018-10-04 | F. Hoffmann-La Roche Ag | Improved antigen binding receptor formats |
| CN110526987A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 靶向cd133的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109735500B (zh) * | 2019-01-25 | 2023-05-16 | 苏州茂行生物科技有限公司 | 一种分泌型靶向cd133的car-t细胞及其制备方法和应用 |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| WO2020243479A1 (en) | 2019-05-31 | 2020-12-03 | The Johns Hopkins University | Bispecific binding agents |
| US20220251222A1 (en) * | 2019-05-31 | 2022-08-11 | The Johns Hopkins University | IL-6Ralpha/IL-8R BISPECIFIC BINDING AGENTS FOR INHIBITING CANCER CELL MIGRATION |
| CN113912696B (zh) * | 2019-07-24 | 2023-05-30 | 暨南大学 | 靶向cd133的结合蛋白与其应用 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN111529690B (zh) * | 2020-06-17 | 2023-03-31 | 中国科学院昆明动物研究所 | 人cd133蛋白1-108肽段的新用途 |
| CN114057875B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| EP4217738A1 (en) * | 2020-09-27 | 2023-08-02 | Genentech, Inc. | High throughput multiparametric immune cell engager screening assay |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| EP4284918A1 (en) | 2021-01-29 | 2023-12-06 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| KR20240019218A (ko) * | 2021-06-04 | 2024-02-14 | 암젠 리서치 (뮌헨) 게엠베하 | T 세포 관여자 분자 및 이의 용도 |
| CN114316050B (zh) * | 2021-12-24 | 2022-11-11 | 北京市神经外科研究所 | Cd133抗体、嵌合抗原受体及其应用 |
| CN114213537B (zh) * | 2021-12-24 | 2022-06-14 | 北京市神经外科研究所 | Cd133抗体、嵌合抗原受体及其应用 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN119654406A (zh) | 2022-07-29 | 2025-03-18 | 艾洛基治疗公司 | 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025056957A1 (en) * | 2023-09-15 | 2025-03-20 | Jimenez Mendoza, Dimas | Peptide based medicines for treating cancer |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN118108849B (zh) * | 2024-04-28 | 2024-06-25 | 苏州睿瀛生物技术有限公司 | 一种抗cd33的纳米抗体制备方法和抗体的荧光标记流式应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2065397A1 (en) * | 2007-11-20 | 2009-06-03 | Miltenyi Biotech GmbH. | Method for the separation of cells |
| EP2769989A1 (en) * | 2013-02-21 | 2014-08-27 | Universitätsklinikum Freiburg | Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the human CD3 T cell receptor |
| WO2016154623A2 (en) * | 2015-03-26 | 2016-09-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-cd133 monoclonal antibodies and related compositions and methods |
| CA2962157A1 (en) * | 2016-10-19 | 2018-04-19 | The Governing Council Of The University Of Toronto | Cd133-binding agents and uses thereof |
-
2017
- 2017-10-19 CN CN201780078237.3A patent/CN110352198B/zh active Active
- 2017-10-19 JP JP2019521046A patent/JP7231158B2/ja active Active
- 2017-10-19 US US16/342,807 patent/US11220551B2/en active Active
- 2017-10-19 EP EP17863201.4A patent/EP3529279A4/en active Pending
- 2017-10-19 WO PCT/CA2017/051245 patent/WO2018072025A1/en not_active Ceased
-
2021
- 2021-10-26 US US17/511,420 patent/US20220073640A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535670A5 (enExample) | ||
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| JP2016500655A5 (enExample) | ||
| HRP20240415T1 (hr) | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba | |
| JP2018532383A5 (enExample) | ||
| JP2019527553A5 (enExample) | ||
| JP2012519492A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| FI3237005T3 (fi) | Bispesifisiä tetravalentteja vasta-aineita sekä menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| JP2018512379A5 (enExample) | ||
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| JP2018505681A5 (enExample) | ||
| JP2020515235A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2020503870A5 (enExample) | ||
| JP2015526387A5 (enExample) | ||
| RU2020120613A (ru) | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения | |
| JP2015163068A5 (enExample) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2018523493A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| MX2022014790A (es) | Receptores de antígenos quiméricos específicos de p95her2 y usos de estos. |